Repurposing Lithium for Parkinson's Disease - Trial NCT06099886
Access comprehensive clinical trial information for NCT06099886 through Pure Global AI's free database. This Phase 1 trial is sponsored by State University of New York at Buffalo and is currently Not yet recruiting. The study focuses on Parkinson's Disease. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
State University of New York at Buffalo
Timeline & Enrollment
Phase 1
Oct 01, 2023
May 01, 2025
Primary Outcome
MRI-derived free water (FW) levels,Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression.
Summary
This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and
 blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06099886
Non-Device Trial